Titre : Processus néoplasiques

Processus néoplasiques : Questions médicales fréquentes

Termes MeSH sélectionnés :

Disability Evaluation

Questions fréquentes et termes MeSH associés

Diagnostic 5

#1

Comment diagnostiquer un cancer ?

Le diagnostic repose sur des examens cliniques, imageries et biopsies.
Diagnostic du cancer Biopsie
#2

Quels tests sont utilisés pour le dépistage ?

Les tests incluent mammographies, coloscopies et tests sanguins spécifiques.
Dépistage du cancer Mammographie
#3

Qu'est-ce qu'une biopsie ?

Une biopsie consiste à prélever un échantillon de tissu pour analyse histologique.
Biopsie Analyse histologique
#4

Quels sont les marqueurs tumoraux ?

Les marqueurs tumoraux sont des substances produites par les cellules cancéreuses, détectables dans le sang.
Marqueurs tumoraux Cancer
#5

Comment évaluer le stade d'un cancer ?

Le stade est évalué par des examens d'imagerie et des classifications comme TNM.
Stadification du cancer Imagerie médicale

Symptômes 5

#1

Quels sont les symptômes courants du cancer ?

Les symptômes incluent fatigue, perte de poids, douleurs et changements cutanés.
Symptômes du cancer Fatigue
#2

Comment reconnaître une tumeur ?

Une tumeur peut se manifester par une masse palpable, des douleurs ou des changements fonctionnels.
Tumeur Douleur
#3

Quels signes indiquent un cancer avancé ?

Les signes incluent des douleurs persistantes, des saignements inexpliqués et des troubles respiratoires.
Cancer avancé Saignement
#4

Les symptômes varient-ils selon le type de cancer ?

Oui, chaque type de cancer présente des symptômes spécifiques selon l'organe touché.
Types de cancer Symptômes
#5

Qu'est-ce que la cachexie ?

La cachexie est une perte de poids et de masse musculaire souvent associée au cancer.
Cachexie Perte de poids

Prévention 5

#1

Comment prévenir le cancer ?

La prévention inclut un mode de vie sain, l'évitement du tabac et des dépistages réguliers.
Prévention du cancer Mode de vie sain
#2

Le vaccin contre le HPV prévient-il le cancer ?

Oui, le vaccin contre le HPV réduit le risque de cancers liés au virus, comme le cancer du col.
Vaccin HPV Cancer du col
#3

Quels aliments aident à prévenir le cancer ?

Les fruits, légumes, grains entiers et aliments riches en antioxydants sont bénéfiques.
Alimentation Antioxydants
#4

L'exercice physique réduit-il le risque de cancer ?

Oui, l'exercice régulier est associé à un risque réduit de plusieurs types de cancer.
Exercice physique Risque de cancer
#5

Le dépistage précoce est-il important ?

Oui, le dépistage précoce permet de détecter le cancer à un stade plus traitable.
Dépistage précoce Cancer

Traitements 5

#1

Quels sont les traitements standards du cancer ?

Les traitements incluent chirurgie, chimiothérapie, radiothérapie et immunothérapie.
Chimiothérapie Radiothérapie
#2

Qu'est-ce que l'immunothérapie ?

L'immunothérapie utilise le système immunitaire pour combattre les cellules cancéreuses.
Immunothérapie Système immunitaire
#3

Comment fonctionne la radiothérapie ?

La radiothérapie utilise des rayonnements pour détruire les cellules cancéreuses.
Radiothérapie Rayonnements
#4

Quels sont les effets secondaires de la chimiothérapie ?

Les effets secondaires incluent nausées, fatigue, perte de cheveux et infections.
Chimiothérapie Effets secondaires
#5

Quand est-ce que la chirurgie est nécessaire ?

La chirurgie est souvent nécessaire pour retirer des tumeurs localisées ou pour un diagnostic.
Chirurgie Tumeur

Complications 5

#1

Quelles sont les complications du cancer ?

Les complications incluent métastases, infections, et effets secondaires des traitements.
Complications du cancer Métastases
#2

Comment les métastases affectent-elles le traitement ?

Les métastases compliquent le traitement et peuvent nécessiter des approches plus agressives.
Métastases Traitement du cancer
#3

Qu'est-ce que la douleur cancéreuse ?

La douleur cancéreuse est causée par la tumeur ou les traitements, nécessitant une gestion adéquate.
Douleur cancéreuse Gestion de la douleur
#4

Les traitements peuvent-ils causer des complications ?

Oui, les traitements comme la chimiothérapie peuvent entraîner des complications comme des infections.
Chimiothérapie Complications
#5

Comment gérer les effets secondaires des traitements ?

La gestion inclut des médicaments, des soins de soutien et des conseils nutritionnels.
Effets secondaires Soins de soutien

Facteurs de risque 5

#1

Quels sont les principaux facteurs de risque du cancer ?

Les facteurs incluent le tabagisme, l'alcool, l'obésité et l'exposition à des agents carcinogènes.
Facteurs de risque Tabagisme
#2

L'hérédité joue-t-elle un rôle dans le cancer ?

Oui, des antécédents familiaux de cancer augmentent le risque de certains types de cancer.
Hérédité Antécédents familiaux
#3

Le stress est-il un facteur de risque ?

Le stress chronique peut influencer le risque de cancer, bien que les preuves soient variées.
Stress Risque de cancer
#4

L'exposition à des produits chimiques augmente-t-elle le risque ?

Oui, l'exposition à des produits chimiques comme l'amiante ou le benzène est un facteur de risque.
Produits chimiques Risque de cancer
#5

L'alimentation influence-t-elle le risque de cancer ?

Oui, une alimentation riche en graisses et pauvre en fibres peut augmenter le risque de cancer.
Alimentation Risque de cancer
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Processus néoplasiques : Questions médicales les plus fréquentes", "headline": "Processus néoplasiques : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Processus néoplasiques : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-04-18", "dateModified": "2025-04-13", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Processus néoplasiques" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Processus pathologiques", "url": "https://questionsmedicales.fr/mesh/D010335", "about": { "@type": "MedicalCondition", "name": "Processus pathologiques", "code": { "@type": "MedicalCode", "code": "D010335", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C23.550" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Anaplasie", "alternateName": "Anaplasia", "url": "https://questionsmedicales.fr/mesh/D000708", "about": { "@type": "MedicalCondition", "name": "Anaplasie", "code": { "@type": "MedicalCode", "code": "D000708", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C23.550.727.045" } } }, { "@type": "MedicalWebPage", "name": "Carcinogenèse", "alternateName": "Carcinogenesis", "url": "https://questionsmedicales.fr/mesh/D063646", "about": { "@type": "MedicalCondition", "name": "Carcinogenèse", "code": { "@type": "MedicalCode", "code": "D063646", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C23.550.727.098" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Transformation cellulaire néoplasique", "alternateName": "Cell Transformation, Neoplastic", "url": "https://questionsmedicales.fr/mesh/D002471", "about": { "@type": "MedicalCondition", "name": "Transformation cellulaire néoplasique", "code": { "@type": "MedicalCode", "code": "D002471", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C23.550.727.098.500" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Crise blastique", "alternateName": "Blast Crisis", "url": "https://questionsmedicales.fr/mesh/D001752", "about": { "@type": "MedicalCondition", "name": "Crise blastique", "code": { "@type": "MedicalCode", "code": "D001752", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C23.550.727.098.500.110" } } } ] }, { "@type": "MedicalWebPage", "name": "Crise blastique", "alternateName": "Blast Crisis", "url": "https://questionsmedicales.fr/mesh/D001752", "about": { "@type": "MedicalCondition", "name": "Crise blastique", "code": { "@type": "MedicalCode", "code": "D001752", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C23.550.727.098.500.110" } } }, { "@type": "MedicalWebPage", "name": "Cocancérogenèse", "alternateName": "Cocarcinogenesis", "url": "https://questionsmedicales.fr/mesh/D003043", "about": { "@type": "MedicalCondition", "name": "Cocancérogenèse", "code": { "@type": "MedicalCode", "code": "D003043", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C23.550.727.098.750" } } } ] }, { "@type": "MedicalWebPage", "name": "Invasion tumorale", "alternateName": "Neoplasm Invasiveness", "url": "https://questionsmedicales.fr/mesh/D009361", "about": { "@type": "MedicalCondition", "name": "Invasion tumorale", "code": { "@type": "MedicalCode", "code": "D009361", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C23.550.727.645" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Infiltration leucémique", "alternateName": "Leukemic Infiltration", "url": "https://questionsmedicales.fr/mesh/D017254", "about": { "@type": "MedicalCondition", "name": "Infiltration leucémique", "code": { "@type": "MedicalCode", "code": "D017254", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C23.550.727.645.500" } } } ] }, { "@type": "MedicalWebPage", "name": "Métastase tumorale", "alternateName": "Neoplasm Metastasis", "url": "https://questionsmedicales.fr/mesh/D009362", "about": { "@type": "MedicalCondition", "name": "Métastase tumorale", "code": { "@type": "MedicalCode", "code": "D009362", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C23.550.727.650" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Extension extranodale", "alternateName": "Extranodal Extension", "url": "https://questionsmedicales.fr/mesh/D000079822", "about": { "@type": "MedicalCondition", "name": "Extension extranodale", "code": { "@type": "MedicalCode", "code": "D000079822", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C23.550.727.650.280" } } }, { "@type": "MedicalWebPage", "name": "Métastase lymphatique", "alternateName": "Lymphatic Metastasis", "url": "https://questionsmedicales.fr/mesh/D008207", "about": { "@type": "MedicalCondition", "name": "Métastase lymphatique", "code": { "@type": "MedicalCode", "code": "D008207", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C23.550.727.650.560" } } }, { "@type": "MedicalWebPage", "name": "Micrométastase tumorale", "alternateName": "Neoplasm Micrometastasis", "url": "https://questionsmedicales.fr/mesh/D061206", "about": { "@type": "MedicalCondition", "name": "Micrométastase tumorale", "code": { "@type": "MedicalCode", "code": "D061206", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C23.550.727.650.695" } } }, { "@type": "MedicalWebPage", "name": "Essaimage tumoral", "alternateName": "Neoplasm Seeding", "url": "https://questionsmedicales.fr/mesh/D009366", "about": { "@type": "MedicalCondition", "name": "Essaimage tumoral", "code": { "@type": "MedicalCode", "code": "D009366", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C23.550.727.650.830" } } }, { "@type": "MedicalWebPage", "name": "Métastases d'origine inconnue", "alternateName": "Neoplasms, Unknown Primary", "url": "https://questionsmedicales.fr/mesh/D009382", "about": { "@type": "MedicalCondition", "name": "Métastases d'origine inconnue", "code": { "@type": "MedicalCode", "code": "D009382", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C23.550.727.650.895" } } }, { "@type": "MedicalWebPage", "name": "Cellules tumorales circulantes", "alternateName": "Neoplastic Cells, Circulating", "url": "https://questionsmedicales.fr/mesh/D009360", "about": { "@type": "MedicalCondition", "name": "Cellules tumorales circulantes", "code": { "@type": "MedicalCode", "code": "D009360", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C23.550.727.650.900" } } } ] }, { "@type": "MedicalWebPage", "name": "Récidive tumorale locale", "alternateName": "Neoplasm Recurrence, Local", "url": "https://questionsmedicales.fr/mesh/D009364", "about": { "@type": "MedicalCondition", "name": "Récidive tumorale locale", "code": { "@type": "MedicalCode", "code": "D009364", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C23.550.727.655" } } }, { "@type": "MedicalWebPage", "name": "Maladie résiduelle", "alternateName": "Neoplasm, Residual", "url": "https://questionsmedicales.fr/mesh/D018365", "about": { "@type": "MedicalCondition", "name": "Maladie résiduelle", "code": { "@type": "MedicalCode", "code": "D018365", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C23.550.727.700" } } }, { "@type": "MedicalWebPage", "name": "Dépendance oncogène", "alternateName": "Oncogene Addiction", "url": "https://questionsmedicales.fr/mesh/D000074723", "about": { "@type": "MedicalCondition", "name": "Dépendance oncogène", "code": { "@type": "MedicalCode", "code": "D000074723", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C23.550.727.850" } } } ], "about": { "@type": "MedicalCondition", "name": "Processus néoplasiques", "alternateName": "Neoplastic Processes", "code": { "@type": "MedicalCode", "code": "D009385", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Barbara A Centeno", "url": "https://questionsmedicales.fr/author/Barbara%20A%20Centeno", "affiliation": { "@type": "Organization", "name": "Department of Pathology, Moffitt Cancer Center, Tampa, Florida, USA, Barbara.Centeno@moffitt.org." } }, { "@type": "Person", "name": "Sarah C Thomas", "url": "https://questionsmedicales.fr/author/Sarah%20C%20Thomas", "affiliation": { "@type": "Organization", "name": "Office of Chief Medical Examiner, New York, New York, USA." } }, { "@type": "Person", "name": "Guoqiang Zeng", "url": "https://questionsmedicales.fr/author/Guoqiang%20Zeng", "affiliation": { "@type": "Organization", "name": "Urological Department, First Hospital of Jilin University, Changchun 130021, Jilin Province, China." } }, { "@type": "Person", "name": "Honglan Zhou", "url": "https://questionsmedicales.fr/author/Honglan%20Zhou", "affiliation": { "@type": "Organization", "name": "Urological Department, First Hospital of Jilin University, Changchun 130021, Jilin Province, China." } }, { "@type": "Person", "name": "Yuantao Wang", "url": "https://questionsmedicales.fr/author/Yuantao%20Wang", "affiliation": { "@type": "Organization", "name": "Urological Department, First Hospital of Jilin University, Changchun 130021, Jilin Province, China. Electronic address: wangyuantaobs@jlu.edu.cn." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Psychometric evaluation of the WHODAS 2.0 and prevalence of disability in a Swedish general population.", "datePublished": "2023-04-05", "url": "https://questionsmedicales.fr/article/37020121", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s41687-023-00580-0" } }, { "@type": "ScholarlyArticle", "name": "Health disparities associated with access to disability evaluations for toddlers in Early Head Start.", "datePublished": "2022-12-27", "url": "https://questionsmedicales.fr/article/36575049", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/jir.13003" } }, { "@type": "ScholarlyArticle", "name": "Multidimensional Disability Evaluation and Confirmatory Analysis of Older Adults in a Home-Based Community in China.", "datePublished": "2022-06-21", "url": "https://questionsmedicales.fr/article/35801251", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fpubh.2022.899303" } }, { "@type": "ScholarlyArticle", "name": "Evaluation of Disability Progression in Multiple Sclerosis via Magnetic-Resonance-Based Deep Learning Techniques.", "datePublished": "2022-09-13", "url": "https://questionsmedicales.fr/article/36142563", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/ijms231810651" } }, { "@type": "ScholarlyArticle", "name": "Health professionals' experiences with the PEDI-UG: What do Ugandan occupational therapists say about the utility and value of the Pediatric Evaluation of Disability Inventory (PEDI-UG) for children with disabilities?", "datePublished": "2022-10-28", "url": "https://questionsmedicales.fr/article/36251008", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/cch.13071" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "États, signes et symptômes pathologiques", "item": "https://questionsmedicales.fr/mesh/D013568" }, { "@type": "ListItem", "position": 3, "name": "Processus pathologiques", "item": "https://questionsmedicales.fr/mesh/D010335" }, { "@type": "ListItem", "position": 4, "name": "Processus néoplasiques", "item": "https://questionsmedicales.fr/mesh/D009385" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Processus néoplasiques - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Processus néoplasiques", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-10", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Processus néoplasiques", "description": "Comment diagnostiquer un cancer ?\nQuels tests sont utilisés pour le dépistage ?\nQu'est-ce qu'une biopsie ?\nQuels sont les marqueurs tumoraux ?\nComment évaluer le stade d'un cancer ?", "url": "https://questionsmedicales.fr/mesh/D009385?mesh_terms=Disability+Evaluation#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Processus néoplasiques", "description": "Quels sont les symptômes courants du cancer ?\nComment reconnaître une tumeur ?\nQuels signes indiquent un cancer avancé ?\nLes symptômes varient-ils selon le type de cancer ?\nQu'est-ce que la cachexie ?", "url": "https://questionsmedicales.fr/mesh/D009385?mesh_terms=Disability+Evaluation#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Processus néoplasiques", "description": "Comment prévenir le cancer ?\nLe vaccin contre le HPV prévient-il le cancer ?\nQuels aliments aident à prévenir le cancer ?\nL'exercice physique réduit-il le risque de cancer ?\nLe dépistage précoce est-il important ?", "url": "https://questionsmedicales.fr/mesh/D009385?mesh_terms=Disability+Evaluation#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Processus néoplasiques", "description": "Quels sont les traitements standards du cancer ?\nQu'est-ce que l'immunothérapie ?\nComment fonctionne la radiothérapie ?\nQuels sont les effets secondaires de la chimiothérapie ?\nQuand est-ce que la chirurgie est nécessaire ?", "url": "https://questionsmedicales.fr/mesh/D009385?mesh_terms=Disability+Evaluation#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Processus néoplasiques", "description": "Quelles sont les complications du cancer ?\nComment les métastases affectent-elles le traitement ?\nQu'est-ce que la douleur cancéreuse ?\nLes traitements peuvent-ils causer des complications ?\nComment gérer les effets secondaires des traitements ?", "url": "https://questionsmedicales.fr/mesh/D009385?mesh_terms=Disability+Evaluation#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Processus néoplasiques", "description": "Quels sont les principaux facteurs de risque du cancer ?\nL'hérédité joue-t-elle un rôle dans le cancer ?\nLe stress est-il un facteur de risque ?\nL'exposition à des produits chimiques augmente-t-elle le risque ?\nL'alimentation influence-t-elle le risque de cancer ?", "url": "https://questionsmedicales.fr/mesh/D009385?mesh_terms=Disability+Evaluation#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer un cancer ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur des examens cliniques, imageries et biopsies." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour le dépistage ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests incluent mammographies, coloscopies et tests sanguins spécifiques." } }, { "@type": "Question", "name": "Qu'est-ce qu'une biopsie ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Une biopsie consiste à prélever un échantillon de tissu pour analyse histologique." } }, { "@type": "Question", "name": "Quels sont les marqueurs tumoraux ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Les marqueurs tumoraux sont des substances produites par les cellules cancéreuses, détectables dans le sang." } }, { "@type": "Question", "name": "Comment évaluer le stade d'un cancer ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Le stade est évalué par des examens d'imagerie et des classifications comme TNM." } }, { "@type": "Question", "name": "Quels sont les symptômes courants du cancer ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent fatigue, perte de poids, douleurs et changements cutanés." } }, { "@type": "Question", "name": "Comment reconnaître une tumeur ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Une tumeur peut se manifester par une masse palpable, des douleurs ou des changements fonctionnels." } }, { "@type": "Question", "name": "Quels signes indiquent un cancer avancé ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Les signes incluent des douleurs persistantes, des saignements inexpliqués et des troubles respiratoires." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon le type de cancer ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, chaque type de cancer présente des symptômes spécifiques selon l'organe touché." } }, { "@type": "Question", "name": "Qu'est-ce que la cachexie ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "La cachexie est une perte de poids et de masse musculaire souvent associée au cancer." } }, { "@type": "Question", "name": "Comment prévenir le cancer ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention inclut un mode de vie sain, l'évitement du tabac et des dépistages réguliers." } }, { "@type": "Question", "name": "Le vaccin contre le HPV prévient-il le cancer ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le vaccin contre le HPV réduit le risque de cancers liés au virus, comme le cancer du col." } }, { "@type": "Question", "name": "Quels aliments aident à prévenir le cancer ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Les fruits, légumes, grains entiers et aliments riches en antioxydants sont bénéfiques." } }, { "@type": "Question", "name": "L'exercice physique réduit-il le risque de cancer ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exercice régulier est associé à un risque réduit de plusieurs types de cancer." } }, { "@type": "Question", "name": "Le dépistage précoce est-il important ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le dépistage précoce permet de détecter le cancer à un stade plus traitable." } }, { "@type": "Question", "name": "Quels sont les traitements standards du cancer ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent chirurgie, chimiothérapie, radiothérapie et immunothérapie." } }, { "@type": "Question", "name": "Qu'est-ce que l'immunothérapie ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "L'immunothérapie utilise le système immunitaire pour combattre les cellules cancéreuses." } }, { "@type": "Question", "name": "Comment fonctionne la radiothérapie ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "La radiothérapie utilise des rayonnements pour détruire les cellules cancéreuses." } }, { "@type": "Question", "name": "Quels sont les effets secondaires de la chimiothérapie ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires incluent nausées, fatigue, perte de cheveux et infections." } }, { "@type": "Question", "name": "Quand est-ce que la chirurgie est nécessaire ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "La chirurgie est souvent nécessaire pour retirer des tumeurs localisées ou pour un diagnostic." } }, { "@type": "Question", "name": "Quelles sont les complications du cancer ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent métastases, infections, et effets secondaires des traitements." } }, { "@type": "Question", "name": "Comment les métastases affectent-elles le traitement ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Les métastases compliquent le traitement et peuvent nécessiter des approches plus agressives." } }, { "@type": "Question", "name": "Qu'est-ce que la douleur cancéreuse ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "La douleur cancéreuse est causée par la tumeur ou les traitements, nécessitant une gestion adéquate." } }, { "@type": "Question", "name": "Les traitements peuvent-ils causer des complications ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les traitements comme la chimiothérapie peuvent entraîner des complications comme des infections." } }, { "@type": "Question", "name": "Comment gérer les effets secondaires des traitements ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "La gestion inclut des médicaments, des soins de soutien et des conseils nutritionnels." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque du cancer ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent le tabagisme, l'alcool, l'obésité et l'exposition à des agents carcinogènes." } }, { "@type": "Question", "name": "L'hérédité joue-t-elle un rôle dans le cancer ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux de cancer augmentent le risque de certains types de cancer." } }, { "@type": "Question", "name": "Le stress est-il un facteur de risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Le stress chronique peut influencer le risque de cancer, bien que les preuves soient variées." } }, { "@type": "Question", "name": "L'exposition à des produits chimiques augmente-t-elle le risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exposition à des produits chimiques comme l'amiante ou le benzène est un facteur de risque." } }, { "@type": "Question", "name": "L'alimentation influence-t-elle le risque de cancer ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation riche en graisses et pauvre en fibres peut augmenter le risque de cancer." } } ] } ] }
Dr Olivier Menir

Contenu validé par Dr Olivier Menir

Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale


Validation scientifique effectuée le 13/04/2025

Contenu vérifié selon les dernières recommandations médicales

Auteurs principaux

Barbara A Centeno

2 publications dans cette catégorie

Affiliations :
  • Department of Pathology, Moffitt Cancer Center, Tampa, Florida, USA, Barbara.Centeno@moffitt.org.
  • Department of Oncologic Sciences, Morsani College of Medicine, University of South Florida, Tampa, Florida, USA, Barbara.Centeno@moffitt.org.
Publications dans "Processus néoplasiques" :

Sarah C Thomas

2 publications dans cette catégorie

Affiliations :
  • Office of Chief Medical Examiner, New York, New York, USA.
Publications dans "Processus néoplasiques" :

Guoqiang Zeng

2 publications dans cette catégorie

Affiliations :
  • Urological Department, First Hospital of Jilin University, Changchun 130021, Jilin Province, China.
Publications dans "Processus néoplasiques" :

Honglan Zhou

2 publications dans cette catégorie

Affiliations :
  • Urological Department, First Hospital of Jilin University, Changchun 130021, Jilin Province, China.
Publications dans "Processus néoplasiques" :

Yuantao Wang

2 publications dans cette catégorie

Affiliations :
  • Urological Department, First Hospital of Jilin University, Changchun 130021, Jilin Province, China. Electronic address: wangyuantaobs@jlu.edu.cn.
Publications dans "Processus néoplasiques" :

Jaime Cofre

2 publications dans cette catégorie

Affiliations :
  • Laborato´ rio de Embriologia Molecular e Caˆncer, Federal University of Santa Catarina, Floriano´ polis, SC 88040-900, Brazil.

Sevtap Arslan

2 publications dans cette catégorie

Affiliations :
  • Department of Radiology, Suhut State Hospital, 03800, Afyon, Turkey.

Deniz Akata

2 publications dans cette catégorie

Affiliations :
  • Department of Radiology, Hacettepe University School of Medicine, Sihhiye, 06230, Ankara, Turkey.

Jawed Nawabi

2 publications dans cette catégorie

Affiliations :
  • Department of Diagnostic and Interventional Neuroradiology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany. j.nawabi@uke.de.

Christian Thaler

2 publications dans cette catégorie

Affiliations :
  • Department of Diagnostic and Interventional Neuroradiology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany.

Jan Korbecki

1 publication dans cette catégorie

Affiliations :
  • Department of Biochemistry and Medical Chemistry, Pomeranian Medical University in Szczecin, Powstańców Wielkopolskich 72 Av., 70-111 Szczecin, Poland.
Publications dans "Processus néoplasiques" :

Donata Simińska

1 publication dans cette catégorie

Affiliations :
  • Department of Biochemistry and Medical Chemistry, Pomeranian Medical University in Szczecin, Powstańców Wielkopolskich 72 Av., 70-111 Szczecin, Poland.
Publications dans "Processus néoplasiques" :

Klaudyna Kojder

1 publication dans cette catégorie

Affiliations :
  • Department of Anaesthesiology and Intensive Care, Pomeranian Medical University in Szczecin, Unii Lubelskiej 1 St., 71-281 Szczecin, Poland.
Publications dans "Processus néoplasiques" :

Szymon Grochans

1 publication dans cette catégorie

Affiliations :
  • Department of Biochemistry and Medical Chemistry, Pomeranian Medical University in Szczecin, Powstańców Wielkopolskich 72 Av., 70-111 Szczecin, Poland.
Publications dans "Processus néoplasiques" :

Izabela Gutowska

1 publication dans cette catégorie

Affiliations :
  • Department of Medical Chemistry, Pomeranian Medical University in Szczecin, Powstańców Wlkp. 72 Av., 70-111 Szczecin, Poland.
Publications dans "Processus néoplasiques" :

Dariusz Chlubek

1 publication dans cette catégorie

Affiliations :
  • Department of Biochemistry and Medical Chemistry, Pomeranian Medical University in Szczecin, Powstańców Wielkopolskich 72 Av., 70-111 Szczecin, Poland.
Publications dans "Processus néoplasiques" :

Irena Baranowska-Bosiacka

1 publication dans cette catégorie

Affiliations :
  • Department of Biochemistry and Medical Chemistry, Pomeranian Medical University in Szczecin, Powstańców Wielkopolskich 72 Av., 70-111 Szczecin, Poland.
Publications dans "Processus néoplasiques" :

Iwona Jarocka-Karpowicz

1 publication dans cette catégorie

Affiliations :
  • Department of Analytical Chemistry, Medical University of Bialystok, Mickiewicza 2D, 15-222 Bialystok, Poland.
Publications dans "Processus néoplasiques" :

Agnieszka Markowska

1 publication dans cette catégorie

Affiliations :
  • Department of Analytical Chemistry, Medical University of Bialystok, Mickiewicza 2D, 15-222 Bialystok, Poland.
Publications dans "Processus néoplasiques" :

Quinlan Carlson

1 publication dans cette catégorie

Affiliations :
  • Department of Pathology, Banner-University Medical Center, College of Medicine, University of Arizona, Tucson AZ, USA.
Publications dans "Processus néoplasiques" :

Sources (10000 au total)

Psychometric evaluation of the WHODAS 2.0 and prevalence of disability in a Swedish general population.

The World Health Organization Disability Assessment Schedule (WHODAS 2.0) is a generic questionnaire that captures health and disability-related functioning information corresponding to six major life... A cross-sectional survey was performed. Internal consistency reliability was assessed with Cronbach's alpha. The construct validity was evaluated with item-total correlation, Pearson's correlation bet... Three thousand four hundred and eighty two adults aged 19-103 years (response rate 43%) participated. Significantly higher degrees of disability were reported by the oldest age group (≥ 80 years), adu... The psychometric properties of the self-administered Swedish 36-item version of the WHODAS 2.0 are comparable to those of other language versions of the instrument. Data of the prevalence of disabilit...

Health disparities associated with access to disability evaluations for toddlers in Early Head Start.

The aim of this investigation was to examine developmental, sociodemographic and familial factors associated with parent reported access to an evaluation in an Early Head Start sample. Children with d... This study (n = 191) examined how developmental, sociodemographic and parent factors at age 2 were associated with parent reporting the child being evaluated by age 3. Two logistic regression analyses... The first model found that children in the monitoring zone of developmental risk were more likely to be evaluated per parent report if they were born preterm, male, with increased behaviour problems, ... This study highlights barriers associated with access to developmental and disability evaluations for children in at-risk families. Health disparities are negatively associated with children's access ...

Health professionals' experiences with the PEDI-UG: What do Ugandan occupational therapists say about the utility and value of the Pediatric Evaluation of Disability Inventory (PEDI-UG) for children with disabilities?

The Uganda version of Pediatric Evaluation of Disability Inventory (PEDI-UG) was culturally adapted and validated from the PEDI-US, a tool used to evaluate the functional capability of children with o... A qualitative research design was chosen to explore the participants' viewpoints concerning the utility and value of the PEDI-UG for children with disabilities. Purposive sampling was used to recruit ... Several challenges concerning the contextual use of PEDI-UG were reported. For example, PEDI-UG being culturally adapted in two languages (English and Luganda) makes it difficult for health profession... The findings of this study suggest that health professionals are challenged with the use of the PEDI-UG assessment in diverse cultural contexts and/or languages. These challenges are important conside...

Confirmed disability progression as a marker of permanent disability in multiple sclerosis.

The prevention of disability over the long term is the main treatment goal in multiple sclerosis (MS); however, randomized clinical trials evaluate only short-term treatment effects on disability. Thi... In total, 14,802 6-month confirmed disability progression events were identified in 8741 patients from the global MSBase registry. For each 6-month confirmed progression event (13,321 in the developme... The score was based on age, sex, MS phenotype, relapse activity, disability score and its change from baseline, number of affected functional system domains and worsening in six of the domains. In the... Clinicodemographic characteristics of 6-month confirmed disability progression events identify those at high risk of sustained long-term disability. This knowledge will allow future trials to better a...

The impact of resilience on headache disability as measured by the Migraine Disability Assessment (MIDAS).

Our objectives were to examine cross-sectional correlations of headache disability with measures of resilience, anxiety, and depression, and to determine if resilience modified the association between... Resilience is associated with quality of life and functioning among patients with chronic conditions. We investigated whether resilience strongly mitigates headache-related disability as measured by t... We prospectively recruited 160 patients with primary headache disorders seen in a tertiary headache medicine program between February 20, 2018 and August 2, 2019. Each participant completed the MIDAS,... The CDRS-25 score was negatively correlated with the total MIDAS (r = -0.21, p = 0.009), GAD-7 (r = -0.56, p < 0.001), and PHQ-9 scores (r = -0.34, p < 0.001). Well-being inversely correlated with dis... Traits associated with resilience decreased the odds of severe disability from headaches, whereas anxiety, depression, and headache frequency were strongly associated with higher disability from heada...

Clinically meaningful change: evaluation of the Rasch-built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS) and the ALSFRS-R.

To investigate clinically meaningful change for ROADS and ALSFRS-R using a patient-defined approach.... Data were reviewed from participants assessed at the Emory ALS Center from 2019-2022 with two assessments using both ROADS and ALSFRS-R and a completed patient-reported global impression of change sca... Data were included from 162 participants. For ROADS (total possible normed score = 146), MID = 5.81 and MDC = 2.83 points. For ALSFRS-R (total possible sum-score = 48), MID = 3.24 and MDC = 1.59 point... Changes that are on average less than 5.81 points (3.98%) on the normed ROADS score or less than 3.24 points (6.75%) on the ALSFRS-R sum-score may not be clinically meaningful according to a patient-d...

Community-based outpatient rehabilitation for the treatment of breast cancer-related upper extremity disability: an evaluation of practice-based evidence.

To evaluate the impact and acceptability of outpatient physical or occupational therapy (PT/OT) for breast cancer survivors (BCS) with varying levels of upper extremity disability (UED).... We retrospectively extracted patient and therapy characteristics, UED measured by quick-disabilities of the arm, shoulder and hand (QuickDASH, 0-100 pts.), and patient-rated acceptability (1-item, 0-1... Patients (N = 417) were 59.89 ± 12.06 years old, 99% female, and attended approximately 10 PT/OT sessions (IQR = 6.0-16.0). Most had high baseline UED (62%), followed by moderate (25%) or low UED (13%... Outpatient cancer rehabilitation is associated with significant improvement in UED for BCS and was acceptable to patients regardless of UED severity at baseline....

Adaption and psychometric evaluation of the Hindi version of Neck Disability Index in the rural population of Northern India: A cross cultural study.

To ensure the validity and therapeutic utility of the Neck disability index (NDI) scale, translations, cultural adaptations and psychometric evidence is necessary. This study aimed to address the abse... Following guidelines provided by the American Association of Orthopedic Surgeons, the original English NDI scale was cross-culturally adapted into Hindi. The adaptation process included translations (... The NDI-Hi version exhibited favorable psychometric properties, including good test-retest reliability with an intra-class correlation coefficient (ICC) of 0.87. Internal consistency of the scale was ... The NDI-Hi demonstrated validity and reliability as an outcome tool for assessing neck disability. It can be effectively utilized in clinical practice and research settings involving Hindi-speaking in...